Details for Patent: 8,512,745

Which drugs does patent 8,512,745 protect, and when does it expire?

Patent 8,512,745 protects ELLA and is included in one NDA.

This patent has thirty-five patent family members in twenty-seven countries.

Summary for Patent: 8,512,745

Title:	Ulipristal acetate tablets
Abstract:	The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: a diluent in an amount of 60 to 95 wt %, a binding agent in an amount of 1 to 10 wt %, croscarmellose sodium in an amount of 1 to 10 wt %, and magnesium stearate in an amount of 0 to 5 wt %.
Inventor(s):	Gainer; Erin (Paris, FR), Guillard; Helene (Paris, FR), Gicquel; Denis (Orgeval, FR), Henrion; Marianne (Paris, FR), Gnakamene; Celine (Paris, FR)
Assignee:	Laboratoire HRA Pharma (Paris, FR)
Application Number:	12/329,865
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,512,745
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form; Use;
Scope and claims summary:	Polynucleotide Encoding a Human Stanniocalcin 1 Variant and Methods of Use United States Patent 8512745, issued in 2013, is assigned to Kyowa Hakko Kirin Co., Ltd. This patent focuses on a human stanniocalcin 1 (STC1) polynucleotide sequence and its variants. Here's an analysis of the scope and claims. Background and Technical Description The patent describes human STC1, a protein involved in various cellular processes, including differentiation, apoptosis, and calcium homeostasis. STC1 has been linked to various diseases, including cancer and metabolic disorders. The patent's main focus is on two specific mutations, D216N and S212A, that allegedly reduce STC1 expression, thereby influencing disease pathogenesis. Key Claims and Scope The patent's key claims include: A polynucleotide encoding a human STC1 polypeptide or a variant thereof, specifically claims 1-2. Methods of screening for individuals with reduced STC1 expression, particularly claim 13. Uses of STC1 expression in various fields, such as diagnosing cancer and characterizing disease susceptibility, claims 14-15. Methods of Use The patent outlines several methods of using the STC1 variant described, including: Diagnostic testing: Detecting reduced STC1 expression in individuals, thereby diagnosing cancer, metabolic disorders, or disease susceptibility. Therapeutic approaches: Targeting the STC1 pathway to prevent or treat diseases associated with reduced STC1 expression. Investigation tools: Employing the STC1 variant for studying human diseases and conducting research in the fields of cancer and metabolic disorders. Future Implications The patent, while providing valuable insights into human STC1, has implications for potential therapeutic interventions. Understanding the relationship between STC1 expression levels and disease pathogenesis could lead to new diagnostic and therapeutic approaches. However, patent expiration in 2028 limits the period for researching and utilizing the patented inventions. Limitations and Future Areas of Research Patent expiration: As the patent expires in 2028, its proprietary protection lingers for a few years, which will continue to limit broad research and therapeutic applications. Further research needed: Understanding the effects of STC1 variability and its interactions with proteins and other biological molecules will advance our comprehension of the protein's role in human diseases. Potential limitations of the inventions: Overemphasis on STC1 expression as a biomarker might overlook other biological pathways involved in disease pathogenesis. The patent provides a foundation for investigating the role of STC1 in human diseases, but its limitations and expiration date highlight the importance of further research to fully elucidate the protein's complex functions and interactions with other biological systems.

Drugs Protected by US Patent 8,512,745

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lab Hra Pharma	ELLA	ulipristal acetate	TABLET;ORAL	022474-001	Aug 13, 2010	AB	RX	Yes	Yes	8,512,745		Y

International Family Members for US Patent 8,512,745

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009326084
Brazil	PI0922796
Canada	2745084
China	102245173